Metraipolis › archive › dc_6934a4c8cd07
Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41760772
- DOI
- 10.1038/s41746-[numero omesso]-w
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-06T17:57:28.567Z
- SHA-256 of the archived text
b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809- Stable URL of this page
https://metraipolis.com/documento/dc_6934a4c8cd07
How to cite
Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772 — Europe PMC (en), https://europepmc.org/article/MED/41760772 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6934a4c8cd07 (Metraipolis archive dc_6934a4c8cd07, sha256 b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809)
BibTeX
@misc{dc6934a4c8cd07,
title = {Methodological and regulatory considerations for causal AI in drug development — Europe PMC PMID:41760772},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41760772},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6934a4c8cd07; sha256 b397b7a33ee66b7e8fc10dcad5862c3cb0cb4539b9178f933438a1f798780809},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41760772. Agents can read the archived copy with the MCP tool read_document.